Orforglipron vs. tirzepatide: weight loss pill vs. injection

With the recent approval of the Wegovy pill, people taking injectable tirzepatide (Mounjaro, Zepbound) may be wondering when they can expect a tablet version of the drug. For now, the closest alternative is orforglipron — although it’s not yet available, and it’s not quite correct to call it an oral tirzepatide.

Read on as we compare orforglipron vs. tirzepatide and break down the main differences between the two drugs.

Tirzepatide is a weekly injection made by Eli Lilly that is available under two brand names:

• Mounjaro, which is approved by the US Food and Drug Administration (FDA) to treat type 2 diabetes in adults and children ages 10 years and older, when combined with diet and exercise.

• Zepbound, which is FDA-approved for weight loss in adults with obesity (or with overweight and a weight-related health condition) and for obstructive sleep apnea, when combined with diet and exercise.

• Orforglipron is a daily oral tablet that Eli Lilly submitted to the FDA for approval for weight loss in late 2025 and that Lilly plans to submit for type 2 diabetes in 2026.

*Note: Information about orforglipron is based on clinical trials because it has not yet been approved by the FDA.

See if you qualify

Tirzepatide is generally more effective than orforglipron at lowering blood sugar and body weight. 

Which is more effective for weight loss? 

Tirzepatide may be more effective for weight loss than orforglipron, according to research. However, we can’t directly compare the two because they weren’t studied in a head-to-head trial for weight loss.

• In a 72-week clinical trial of tirzepatide, people with obesity lost 15%–22% of their starting body weight, depending on the dose. 

• In a 72-week trial of orforglipron, people with obesity lost 7.5%–11.2% of their starting body weight, depending on the dose. However, a separate trial found that people taking a higher dose (45 mg) lost up to 14.7% of their body weight in 36 weeks. (Comparatively, people taking tirzepatide lost over 16% in that time frame.)

Which is more effective for blood sugar control? 

Tirzepatide may be more effective for blood sugar control than orforglipron, according to research (again, they haven’t been directly compared in a head-to-head trial):

• In clinical trials, tirzepatide lowered A1C levels by 1.87%–2.59%.

• In clinical trials, orforglipron lowered A1C levels by 1.24%–1.6%.

Orforglipron and tirzepatide work similarly in the body to lower body weight and blood sugar levels. Both drugs mimic the hormone GLP-1 (glucagon-like peptide-1). However, tirzepatide additionally mimics another hormone: GIP (glucose-dependent insulinotropic polypeptide).

Orforglipron 

As a GLP-1 receptor agonist, orforglipron mimics the GLP-1 hormone and activates its receptors throughout the body. This helps with weight loss and blood sugar levels by:

• Slowing down digestion, so you feel full sooner and longer

• Stimulating the release of insulin, while reducing glucagon, to prevent blood sugar spikes after you eat

• Reducing appetite, so you eat less food

Tirzepatide 

Tirzepatide is unique among GLP-1 drugs because it’s technically a GLP-1 and GIP drug. Mimicking two gut hormones rather than just one could be a reason that tirzepatide produces greater weight loss and better blood sugar control than orforglipron in their respective clinical trials.

A major difference between orforglipron vs. tirzepatide is how they’re taken. Orforglipron is a daily pill, whereas tirzepatide is a weekly injection.

Orforglipron 

Orforglipron is an oral tablet that you take once daily. 

How to take it: Take orforglipron by mouth, with or without food.

Doses: Since orforglipron is not yet FDA-approved, we don’t know the official dosage strengths. In clinical trials, various dosage strengths have been studied, including the doses used for titration (dose increases used to gradually work up to the target dose). They include 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg, and 45 mg.

Starting dose: We don’t know the starting dosage strength of orforglipron yet, but it may be as low as 2 mg–3 mg, based on the research.

Maintenance doses: We don’t yet know the maintenance dosage strengths of orforglipron, but research shows it can be effective for weight loss at 24 mg, 36 mg, and 45 mg.

Maximum dose: We don’t know the maximum dosage strength of orforglipron yet, but it may be 36 mg or 45 mg, based on the research. The most recent weight loss and type 2 diabetes trials did not use doses higher than 36 mg daily.

Dosing schedule: In clinical trials, participants started at a low dose and then increased their dose every four weeks until they reached their maintenance dose.

Tirzepatide 

Tirzepatide is an injectable medication that you take weekly, on the same day of the week each week.

How to take it: Tirzepatide is injected subcutaneously (under the skin) of the abdomen, thigh, or upper arm. You inject it once a week on the same day each week and rotate injection sites with each injection.

Doses: Tirzepatide is available in six dosage strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.

Starting dose: 2.5 mg

Maintenance doses: 5 mg, 10 mg, or 15 mg

Maximum dose: 15 mg

Dosing schedule: Providers typically prescribe a starting dose of 2.5 mg weekly. From there, they may increase your dose in 2.5 mg every four weeks until you reach a maintenance dose that works for you.

As GLP-1 medications, orforglipron and tirzepatide share many similar gastrointestinal side effects due to their effects on the digestive system.

The most common side effects of both orforglipron and tirzepatide are:

• Nausea

• Constipation

• Vomiting

• Diarrhea

• Upset stomach

• Belching 

With both medications, the GI side effects tend to be mild to moderate and are most common when starting the medication or increasing your dose.

We won't know the full risk profile for orforglipron until it’s officially FDA-approved. Risks and precautions for tirzepatide include:

• Acute pancreatitis

• Diabetic retinopathy complications (diabetes-related vision changes)

• Hypoglycemia (low blood sugar), especially when used with insulin

• Kidney or gallbladder issues

• Severe gastrointestinal reactions

• Allergic reactions

• Pulmonary aspiration during general anesthesia or deep sedation

All GLP-1s, including tirzepatide, carry a box warning for thyroid tumors based on animal studies. While it’s unknown if GLP-1s have the same effect in humans, people with a personal or family history of thyroid cancer should not take tirzepatide. 

Orforglipron may also carry some of these same warnings, but we won’t know for sure until it’s approved by the FDA.

See if you qualify

Without insurance, orforglipron is expected to cost less than tirzepatide once it becomes available. 

Orforglipron 

Orforglipron will cost $149–$399 per month, depending on the dose, when purchased through Eli Lilly’s LillyDirect self-pay pharmacy. The lowest dose will cost $149, and other doses may cost up to $399.

Tirzepatide 

Without insurance, tirzepatide can cost as little as $299 to over $1,000 per month, depending on the brand name, dosage strength, and pharmacy.

• Mounjaro has a list price of $1,112.16 per month.

• Zepbound has a list price of $1,086.37 per month. 

• Zepbound vials have a cash price of $299–$449 per month 

If you have commercial drug insurance, you may be eligible to get Mounjaro or Zepbound for as low as $25 per month with Eli Lilly’s official savings card programs. 

• To get tirzepatide for $25, you must have a commercial insurance plan that covers Mounjaro or Zepbound. 

• If your plan doesn’t include coverage, the program brings your price down to as low as $499 per month. People with government-funded insurance are not eligible.

Choosing between orforglipron and tirzepatide is easy right now since only one (tirzepatide) is currently available. Once orforglipron gets approved, here are some key decision factors you may want to consider:

1. Your weight loss goals. Tirzepatide drives more weight loss than orforglipron based on data from separate clinical trials. This may make it a better fit for people who want to lose more weight.

2. Your comfort with injections. Tirzepatide is available exclusively as an injection, whereas orforglipron is an oral medication.

3. Your preferences. Some people prefer the once-weekly dosing of tirzepatide, while others may prefer the routine of a daily pill like orforglipron.

4. Your insurance coverage. The best option for you may come down to budget and which medication your insurance covers.

Orforglipron and tirzepatide have both proven to be effective medications for weight loss and type 2 diabetes. Here are some of the key differences to keep in mind:

• Only tirzepatide is currently FDA-approved, while orforglipron may be approved later in 2026.

• Tirzepatide is injected once a week, while orforglipron is taken by mouth daily.

• Tirzepatide may produce both more weight loss and blood sugar control than orforglipron.

• Without insurance, orforglipron will cost less than tirzepatide.

• Both drugs are expected to have similar side effects and risks.